uniQure N.V. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings
uniQure N.V. (QURE) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings of -$1.82 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-27.
Financial Statements › Income Statement › Other Income
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings · last filed 2025-02-27
- uniQure N.V. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2017-12-31 was $2.52M, a 39.59% decline year-over-year.
- uniQure N.V. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2017-09-30 was $2.29M.
- uniQure N.V. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2017-06-30 was $289.00K.
- uniQure N.V. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2017-03-31 was $95.00K.
- uniQure N.V. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2024 was -$1.82M, a 111.43% decline from fiscal 2023.
- uniQure N.V. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2023 was $15.89M, a 267.94% increase from fiscal 2022.
- uniQure N.V. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2022 was $4.32M, a 36.87% decline from fiscal 2021.
- uniQure N.V. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2021 was $6.84M.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 12 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 12 month as first filed |
|---|---|---|---|---|---|
| 2024-12-31 | -$1.82M 10-K · filed 2025-02-27 | ||||
| 2023-12-31 | $15.89M 10-K · filed 2025-02-27 | ||||
| 2022-12-31 | $4.32M 10-K · filed 2025-02-27 | ||||
| 2021-12-31 | $6.84M 10-K · filed 2024-02-28 | ||||
| 2020-12-31 | -$2.30M 10-K · filed 2023-02-27 | ||||
| 2019-12-31 | $2.53M 10-K · filed 2022-02-25 | ||||
| 2018-12-31 | -$4.05M 10-K · filed 2021-03-01 | ||||
| 2017-12-31 | $2.52M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | $4.81M derived: sum of 2 quarters · filed 2020-03-02 | $5.10M derived: sum of 3 quarters · filed 2020-03-02 | $5.19M 10-K · filed 2020-03-02 | |
| 2017-09-30 | $2.29M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-01 | $2.58M derived: sum of 2 quarters · filed 2017-11-01 | $2.67M 10-Q · filed 2017-11-01 | $6.84M derived: sum of 4 quarters · filed 2019-02-28 | |
| 2017-06-30 | $289.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-08 | $384.00K 10-Q · filed 2017-08-08 | $4.55M derived: sum of 3 quarters · filed 2019-02-28 | $2.68M derived: sum of 4 quarters · filed 2019-02-28 | |
| 2017-03-31 | $95.00K 10-Q · filed 2017-05-09 | $4.26M derived: sum of 2 quarters · filed 2019-02-28 | $2.39M derived: sum of 3 quarters · filed 2019-02-28 | $2.25M derived: sum of 4 quarters · filed 2019-02-28 | |
| 2016-12-31 | $4.17M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-28 | $2.29M derived: sum of 2 quarters · filed 2019-02-28 | $2.16M derived: sum of 3 quarters · filed 2019-02-28 | $1.90M 10-K · filed 2019-02-28 | -$1.86M 10-K · filed 2017-03-15 |
| 2016-09-30 | -$1.88M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-01 | -$2.01M derived: sum of 2 quarters · filed 2017-11-01 | -$2.27M 10-Q · filed 2017-11-01 | ||
| 2016-06-30 | -$136.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-08 | -$393.00K 10-Q · filed 2017-08-08 | |||
| 2016-03-31 | -$257.00K 10-Q · filed 2017-05-09 | ||||
| 2015-12-31 | $8.50M 10-K · filed 2018-03-14 | ||||
| 2014-12-31 | $181.00K 10-K · filed 2017-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |